Lilly Claims It’s On Pace To Traverse Its Patent Cliff, Meet Financial Guidance Through 2014
This article was originally published in The Pink Sheet Daily
As it prepares for the U.S. patent expiration of blockbuster antidepressant Cymbalta later this year, Lilly says it is meeting three strategic priorities it set in 2009, putting it on a path to return to sustainable growth.
You may also be interested in...
Eli Lilly says R&D and SG&A spending will decline as a percent of sales post-2014, likely resulting in spending cuts, when the company expects to return to sales growth after cycling through important patent losses.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.